List of Excipients in Branded Drug VISTASEAL

« Back to Dashboard

Last updated: September 26, 2026

ecutive summary: VISTASEAL is a plasma-derived fibrin sealant whose commercial value depends on protein stability, pathogen safety, rapid reconstitution, applicator performance, and reliable cold-chain or controlled-temperature logistics. The formulation opportunity is narrower than for conventional tablets because fibrinogen and thrombin are active biologic proteins. The strongest opportunities are in excipient qualification, protein-stabilizing systems, container-closure components, delivery devices, manufacturing efficiency, and adjacent fibrin-sealant products. Generic substitution risk is limited by biologic complexity, manufacturing controls, device integration, and the absence of an Orange Book pathway.

VISTASEAL Excipient Strategy, Patent Position, and Commercial Opportunities

VISTASEAL is a sterile, two-component fibrin sealant containing human fibrinogen and human thrombin. It is marketed by Ethicon, a Johnson & Johnson company, and is used as an adjunct to hemostasis during surgery when conventional surgical techniques are ineffective or impractical.[1]

The product is not a conventional small-molecule drug. Its commercial and intellectual-property profile is closer to a plasma-derived biologic combined with a surgical delivery system.

What is VISTASEAL and how does its formulation work?

VISTASEAL forms a fibrin clot when its fibrinogen and thrombin components are mixed at the bleeding site. Thrombin converts fibrinogen into fibrin, while calcium supports the coagulation reaction.[1]

The product is supplied as separate protein solutions that are prepared before use. This separation reduces premature clot formation and allows the formulation to maintain the fibrinogen and thrombin components independently until application.

VISTASEAL active ingredients and excipients

Public labeling identifies the principal active ingredients and formulation classes, but does not disclose a complete quantitative composition for every formulation component. The labeled components include:

Component	Functional role
Human fibrinogen	Forms the fibrin matrix
Human thrombin	Converts fibrinogen to fibrin
Calcium chloride	Supports thrombin-mediated coagulation
Human albumin	Protein stabilizer and bulking component
Amino acids, including arginine or glycine	Stabilization and tonicity control
Sodium chloride	Tonicity adjustment
Sodium citrate	Buffering and calcium-control function
Sterile water for injection	Reconstitution vehicle

The exact excipient system can vary by component, concentration, manufacturing stage, and presentation. Commercial analysis should therefore rely on the current product label, chemistry, manufacturing and controls documentation, and regulatory filings rather than informal ingredient databases.

What excipient strategy is appropriate for VISTASEAL?

The optimal strategy is to protect protein integrity without impairing clot formation, sprayability, reconstitution, or compatibility with the applicator.

Protein stabilization

Fibrinogen is sensitive to aggregation, denaturation, oxidation, proteolysis, and interfacial stress. Thrombin has a separate stability profile and must retain catalytic activity after storage and reconstitution.

Relevant stabilization levers include:

• Albumin to reduce surface adsorption and protein loss.
• Amino acids such as glycine or arginine to reduce aggregation and improve solubility.
• Controlled ionic strength to preserve protein conformation.
• Citrate or other buffering systems to control pH.
• Low-peroxide excipient grades to limit oxidative degradation.
• Low-binding vial and syringe materials.
• Controlled headspace oxygen and moisture exposure.

A formulation change that improves shelf life but reduces thrombin activity, changes clot kinetics, or increases fibrinogen aggregation may not be commercially useful.

Freeze-dried and reconstituted presentations

For a two-component fibrin sealant, the excipient system must support both storage stability and rapid preparation in an operating room. The product must reconstitute within a clinically practical period, without visible particles, foam, or undissolved material.

Commercially relevant development targets include:

Performance target	Commercial importance
Short reconstitution time	Reduces operating-room delay
Low foaming	Improves dose uniformity and spray quality
High recovery of fibrinogen activity	Supports clot strength
Retained thrombin activity	Supports rapid clot initiation
Stable viscosity	Enables consistent delivery
Low particulate burden	Supports safety and device reliability
Extended temperature tolerance	Reduces logistics cost
Long in-use stability	Supports multi-site surgery

Excipient suppliers can compete by offering qualified grades with low endotoxin, low bioburden, controlled peroxide content, and consistent particle or solution characteristics. Conventional excipient price competition is less important than lot consistency and regulatory documentation.

Device compatibility

VISTASEAL is delivered through an applicator system. The formulation must remain compatible with tubing, nozzles, syringes, seals, and spray or drip configurations.

Critical compatibility risks include:

• Protein adsorption to polymer surfaces.
• Extractables and leachables from tubing or elastomers.
• Nozzle blockage caused by premature clotting.
• Shear-induced protein degradation.
• Inconsistent droplet size or spray pattern.
• Pressure-related loss of activity.
• Residual hold-up volume in the delivery path.

The strongest commercial opportunity may arise from co-development of excipients and delivery devices rather than from an excipient substitution alone.

What excipients are most commercially attractive for VISTASEAL?

The most attractive excipient opportunities are those that solve measurable product or manufacturing problems.

Opportunity	Potential value	Development barrier
Stabilized albumin systems	Reduce adsorption and aggregation	Human-origin sourcing and comparability
Arginine or glycine optimization	Improve solubility and reconstitution	Must preserve clot performance
Low-peroxide excipient grades	Limit oxidative damage	Requires supplier qualification
Improved buffering systems	Extend pH stability	May alter coagulation kinetics
Antioxidant strategies	Reduce protein oxidation	Possible biological or regulatory effects
Surfactant-free stabilization	Reduce leachables and tolerability concerns	May increase interface sensitivity
Novel bulking agents	Improve lyophilized cake and handling	New excipient qualification burden
Container-surface treatments	Reduce protein adsorption	Extractables and scale-up concerns
Temperature-tolerant formulations	Lower cold-chain dependence	Requires extensive stability data

The safest commercial path is usually optimization of already accepted excipients rather than introduction of a novel excipient. New excipients add regulatory, toxicology, and manufacturing obligations that may outweigh the stability benefit.

What FDA regulatory status does VISTASEAL have?

VISTASEAL is an FDA-approved biologic product under Biologics License Application 761083. Its labeled use is as an adjunct to hemostasis in adults undergoing surgery when control of bleeding by conventional surgical techniques is ineffective or impractical.[1,2]

Key regulatory characteristics include:

Regulatory issue	VISTASEAL position
Product category	Plasma-derived fibrin sealant
FDA pathway	Biologics License Application
Active components	Human fibrinogen and human thrombin
Clinical use	Surgical adjunct to hemostasis
Delivery	Two-component applicator system
Orange Book listing	Not listed as a conventional drug product
Reference-product framework	Purple Book biologic framework
Generic pathway	No standard ANDA substitution pathway
Biosimilar risk	Legally possible in principle, technically difficult

Because VISTASEAL is regulated as a biologic, formulation modifications may require a prior-approval supplement, comparability package, or other FDA submission depending on the change. A change to an excipient can affect critical quality attributes, potency, immunogenicity assessment, sterility assurance, and stability.

What is the Orange Book status of VISTASEAL?

VISTASEAL does not have the standard Orange Book exclusivity profile associated with an orally administered small-molecule drug. Biologic products are generally tracked through FDA biologics resources, including the Purple Book, rather than through Orange Book patent certification procedures.[3]

This distinction affects market entry:

• A conventional ANDA Paragraph IV challenge is generally not the principal route against VISTASEAL.
• Patent certifications associated with small-molecule generic filing are not the primary framework.
• A follow-on manufacturer would more likely pursue a biologics license application or biosimilar pathway.
• Device, manufacturing, formulation, and process patents can still create commercial barriers.
• Patent litigation may occur independently of Orange Book listing status.

When does VISTASEAL lose exclusivity?

VISTASEAL’s practical exclusivity does not depend on a single public Orange Book expiration date. Market protection can arise from several layers:

1. Biologic regulatory exclusivity.
2. Formulation and process patents.
3. Delivery-device patents.
4. Plasma sourcing and pathogen-reduction know-how.
5. Manufacturing scale and quality systems.
6. Clinical adoption and hospital contracting.
7. Trade secrets covering purification, stabilization, and filling.

The statutory biologic reference-product exclusivity period is generally 12 years from first licensure under U.S. law, subject to the specific regulatory history of the product and any applicable statutory adjustments.[4] That period does not automatically eliminate patent or manufacturing barriers.

Patent expiration and freedom-to-operate

A complete VISTASEAL patent-expiration analysis requires a live review of USPTO records, assignment data, continuation practice, terminal disclaimers, and litigation dockets. Product-level public sources do not provide a single definitive expiration date for the entire VISTASEAL commercial position.

The relevant patent families are likely to fall into these categories:

Patent category	Typical protected subject matter
Composition	Fibrinogen-thrombin combinations and concentration ranges
Formulation	Stabilizer, buffer, salt, and protein-concentration systems
Process	Purification, viral inactivation, drying, filling, and reconstitution
Device	Dual-barrel syringes, mixing tips, spray nozzles, and applicators
Method of use	Surgical hemostasis and application techniques
Packaging	Vial, syringe, tray, and temperature-control configurations

A competitor should conduct claim-level analysis rather than rely on product-name searches. The highest-risk claims are typically those directed to specific protein ratios, stabilizer combinations, delivery configurations, or manufacturing conditions.

Are Paragraph IV challenges likely for VISTASEAL?

A conventional Paragraph IV challenge is unlikely to be the primary entry mechanism because VISTASEAL is a biologic rather than an Orange Book-listed small molecule.

A competing manufacturer could instead:

• Develop a biosimilar or other follow-on biologic.
• File a standalone BLA for a fibrin sealant.
• Challenge patents through declaratory judgment or infringement litigation.
• Design around formulation or applicator claims.
• Enter through a different product configuration or indication.
• Compete with another approved fibrin sealant without establishing interchangeability.

The technical burden is high because a follow-on product must address differences in source plasma, donor screening, purification, viral clearance, protein composition, fibrin architecture, thrombin activity, clot strength, sterility, and delivery performance.

How strong is the VISTASEAL patent estate?

The estate is likely strongest where formulation, process, and device claims overlap. A formulation patent alone may be easier to design around than a patent covering a complete manufacturing and delivery system.

Strength factors

• Human plasma-derived starting materials create complex quality constraints.
• The two-component format supports device and formulation claim layering.
• Protein activity and clot kinetics can provide meaningful technical differentiation.
• Manufacturing know-how may remain protected as trade secrets.
• Applicator design can create a separate enforcement and licensing position.

Weakness factors

• Broad claims to fibrin sealants may face prior-art pressure.
• Many excipients are established pharmaceutical materials.
• Alternative protein concentrations may avoid narrow formulation claims.
• Competitors can pursue different delivery systems.
• Patent expiration does not prevent technical workarounds once manufacturing capability is established.

The commercial estate may therefore be more durable than a simple composition patent, but its strength depends on claim scope, prosecution history, remaining term, and the ability to prove infringement from public product information.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not bulk supply of common sodium chloride or glycine. It is qualification of high-purity, biologically compatible materials supported by regulatory documentation.

High-value supplier opportunities

Qualified protein-stabilization platforms

Suppliers can offer albumin, amino acids, buffers, and low-peroxide materials with:

• Tight impurity specifications.
• Consistent microbial and endotoxin control.
• Viral and adventitious-agent documentation where relevant.
• Extractables and leachables data.
• Multi-site manufacturing.
• Regulatory support for global filings.

Lyophilization and reconstitution systems

A supplier that improves cake structure, residual moisture control, and reconstitution speed can create value without changing the active biologic. This opportunity is strongest if the formulation maintains fibrinogen recovery and thrombin potency after long-term storage.

Cold-chain reduction

VISTASEAL and comparable fibrin sealants may benefit from greater temperature tolerance. A formulation that reduces refrigerated-storage dependence could lower:

• Distribution costs.
• Hospital inventory losses.
• Temperature-excursion waste.
• Emergency-use logistics constraints.

The required evidence includes accelerated stability, real-time stability, potency, sterility, particulate, and container-closure data.

Integrated formulation-device systems

A supplier or contract development organization could provide:

• Dual-chamber delivery systems.
• Low-binding tubing.
• Improved mixing tips.
• Spray nozzles with reduced clogging.
• Closed-system applicators.
• Single-use components with lower residual volume.

This model can create switching costs and generate device, formulation, and manufacturing intellectual property together.

How does VISTASEAL compare with competing fibrin sealants?

VISTASEAL competes with other fibrin sealants, including TISSEEL and EVICEL, rather than with conventional generic drugs alone. Competition is based on clot performance, application method, preparation time, storage, price, surgical specialty, and hospital purchasing contracts.

Product	Core biologic concept	Key competitive dimensions
VISTASEAL	Human fibrinogen plus human thrombin	Application system, hemostatic performance, hospital adoption
TISSEEL	Fibrin sealant with fibrinogen and thrombin components	Established surgical use and delivery formats
EVICEL	Human fibrin sealant	Indication coverage, handling, and contracting
Gelatin or collagen hemostats	Non-fibrin matrix or physical barrier	Lower biologic complexity, different use profile
Oxidized cellulose products	Physical hemostasis	Shelf life, cost, and ease of use

Fibrin-sealant competitors may be more vulnerable to price competition than to direct substitution by an excipient-improved version. The strongest differentiation is likely to come from faster preparation, lower waste, simpler delivery, and reliable clot formation in difficult surgical fields.

What litigation and settlement risks affect VISTASEAL?

No broad conclusion about active VISTASEAL litigation should be drawn from the product label or FDA approval database. Litigation analysis requires current searches of federal court dockets, USPTO records, and relevant patent assignments.

Potential dispute areas include:

• Patent infringement involving fibrin-sealant formulations.
• Applicator and mixing-device patents.
• Plasma sourcing and purification technology.
• Trade-secret disputes involving manufacturing processes.
• Contract disputes with excipient or device suppliers.
• Product-liability claims involving thrombosis, hypersensitivity, or viral safety.
• Regulatory disputes over manufacturing changes or labeling.

Unlike the small-molecule market, a typical VISTASEAL settlement would not necessarily involve a fixed generic-entry date. A commercial agreement could instead involve a license, regional supply arrangement, device access, co-development, or cross-license.

What revenue exposure does VISTASEAL create?

Johnson & Johnson publicly reports operating results by major business segments rather than disclosing VISTASEAL revenue as a standalone product line.[5] Public product-level revenue and margin data are therefore limited.

Revenue exposure is linked to:

• Surgical procedure volume.
• Use in cardiovascular, general, vascular, and other procedures.
• Hospital formulary status.
• Product availability and manufacturing continuity.
• Competitive pricing from other fibrin sealants.
• Use of lower-cost mechanical hemostats.
• Reimbursement and operating-room economics.

For investors and licensing teams, the most useful commercial indicators are likely hospital contract wins, geographic approvals, manufacturing capacity, product recalls, supply interruptions, and competitive tender pricing rather than reported product revenue.

What generic launch scenarios exist for VISTASEAL?

Three practical entry scenarios are more relevant than a standard generic launch.

Scenario 1: Follow-on biologic entry

A competitor develops a highly comparable fibrinogen-thrombin product and seeks FDA approval through the applicable biologic pathway. Entry timing depends on regulatory exclusivity, patent disputes, clinical comparability, and manufacturing readiness.

Scenario 2: Independent fibrin-sealant BLA

A company develops a differentiated plasma-derived or recombinant product with its own clinical and CMC package. This route avoids direct dependence on VISTASEAL comparability but requires substantial investment.

Scenario 3: Non-fibrin substitute

A manufacturer competes with collagen, gelatin, oxidized cellulose, polysaccharide, or synthetic hemostatic products. This is the most immediate competitive threat in procurement markets because it does not require biosimilar equivalence.

The lowest-risk commercial entry may be an improved applicator or adjacent hemostatic product rather than a direct VISTASEAL substitute.

What geographic opportunities exist?

The United States is the most important regulatory reference market, but commercial opportunities also exist in Europe, Japan, Canada, Australia, and emerging surgical markets.

Geographic strategy should assess:

• Local biologic licensing requirements.
• Plasma donor and pathogen-screening standards.
• Cold-chain infrastructure.
• Hospital procurement models.
• Patent term and national validations.
• Device registration.
• Reimbursement for surgical hemostats.
• Local manufacturing or fill-finish incentives.

Emerging markets may have stronger demand for temperature-tolerant products and lower-cost delivery systems. Developed markets may offer higher margins for premium applicators, operating-room workflow improvements, and reduced product waste.

Key Takeaways

• VISTASEAL is a plasma-derived biologic fibrin sealant, not a conventional small-molecule drug.
• Its formulation depends on human fibrinogen, human thrombin, calcium, buffers, salts, amino acids, and protein-stabilization components.
• The best excipient opportunities involve protein stability, reconstitution speed, low-peroxide grades, container compatibility, and temperature tolerance.
• New excipients face a higher regulatory burden than optimized established excipients.
• VISTASEAL is not primarily exposed to a standard Orange Book Paragraph IV challenge.
• Follow-on biologic entry is technically difficult because product quality depends on plasma sourcing, purification, viral clearance, protein activity, and device performance.
• Patent value is likely distributed across formulation, manufacturing, delivery-device, and method-of-use claims.
• Device and formulation co-development may offer more defensible commercial opportunities than commodity excipient supply.
• Public company reporting does not disclose standalone VISTASEAL revenue.
• The most realistic competitive threats include other fibrin sealants and non-fibrin hemostatic products.

FAQs

Can a conventional excipient supplier sell materials for VISTASEAL without a new drug application?

Yes. An excipient supplier generally sells an ingredient to the biologic manufacturer rather than filing an independent drug application. The manufacturer must qualify the material, assess product impact, and document the change in its regulatory filing.

Does VISTASEAL require a biosimilar interchangeability designation?

Not necessarily. A competing fibrin sealant may pursue a biologic approval pathway that does not result in an interchangeable designation. Interchangeability depends on the applicable FDA pathway and supporting evidence.

Could recombinant fibrinogen replace the plasma-derived fibrinogen in VISTASEAL?

A recombinant substitute would be a major product change. It could alter glycosylation, impurity profiles, fibrin structure, clot kinetics, immunogenicity, and regulatory classification. It would more likely support a new or substantially modified biologic product than a routine excipient change.

Which excipient change is most likely to improve hospital economics?

A change that extends temperature tolerance or shortens reconstitution time has the clearest potential to reduce distribution waste and operating-room delay. The change must preserve potency, sterility, clot performance, and device compatibility.

Are VISTASEAL patents likely to block all competing fibrin sealants?

No. Patent rights generally cover defined claim scope rather than the entire fibrin-sealant category. Competitors may design around concentration ranges, excipient combinations, processing conditions, delivery systems, or indications, subject to a current freedom-to-operate analysis.

References

1. U.S. Food and Drug Administration. (2023). VISTASEAL fibrin sealant (human): Prescribing information.
2. U.S. Food and Drug Administration. (2017). VISTASEAL approval letter and biologics license application 761083.
3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
4. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §7002.
5. Johnson & Johnson. (2024). Annual report.